Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

Summary

In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.

Timeline

Start

2024-10-03

Primary completion

2024-12-10

Completion

2024-12-10

Drugs

Indications